Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.
Always refer to full SmPC before prescribing XELJANZ.
Tablets shown in the above image are not true to size.
Packs and tablets shown not true to size.
Explore the resources avaliable for patients who have been prescribed XELJANZ for PsA
†XELJANZ dose should be reduced to 5 mg once daily in patients receiving 11 mg once daily.
Note, the licensed dose of XELJANZ for the treatment of PsA in the UK is 5mg administered twice daily or one 11 mg prolonged-release tablet administered once daily, which should not be exceeded.
AUC - area under curve; Cmax - maximum concentration; MTX - methotrexate; TB - tuberculosis; RA - rheumatoid arthritis; PsA - psoriatic arthritis; OD - once daily
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020